Incorporating founder virus information in vaccine field trials.

about

Sieve analysis using the number of infecting pathogens.

P2860

Q46241496-FAEEBB2C-2F88-410B-89C8-01672794A000

P2860

Incorporating founder virus information in vaccine field trials.

Item

http://www.wikidata.org/entity/Q36509005

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Incorporating founder virus information in vaccine field trials.

@ast

Incorporating founder virus information in vaccine field trials.

@en

type

Item

label

Incorporating founder virus information in vaccine field trials.

@ast

Incorporating founder virus information in vaccine field trials.

@en

prefLabel

Incorporating founder virus information in vaccine field trials.

@ast

Incorporating founder virus information in vaccine field trials.

@en

P1476

Incorporating founder virus information in vaccine field trials.

@en

P2093

Chiung-Yu Huang

http://www.w3.org/2001/XMLSchema#string

Dean Follmann

http://www.w3.org/2001/XMLSchema#string

P2860

Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users.

Augmented designs to assess immune response in vaccine trials

Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization

Evaluating a surrogate endpoint at three levels, with application to vaccine development.

Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.

Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

The analysis of failure times in the presence of competing risks.

P304

386-396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BIOM.12277

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25773491

http://www.w3.org/2001/XMLSchema#string

P932

4729213

http://www.w3.org/2001/XMLSchema#string

Incorporating founder virus information in vaccine field trials.

about

P2860

P2860

Incorporating founder virus information in vaccine field trials.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932